Paul ‘s closing comments from the last CC-worth reading Thank you, team, and thank you guys on the line for your questions. I know this is an exciting time for us. Today's remarks ran a bit longer than usual due to all of our great progress. I just wanted to conclude with some important key takeaways here in this early midterm of the 2022 year.
Theratechnologies is currently hitting on all of our execution marks in realizing the future of the company in the here and now. Most recently, the validation that we receive for our investment thesis and the associated capital infusion that came with it is a real vote of confidence. This is the case despite the challenging market for small cap biotech where financings are just not getting done.
The second important takeaway is that we have successfully reached the end of the dose escalation portion in TH1902, and have established our go-forward dose. We now expect new data to be potentially released in the back half of 2022 with regards to early efficacy of our basket trial. This will be followed in Q1 of 2023 by a presentation of the complete data set for the dose escalation study, which has already established dose limiting toxicity in addition to the go-forward dose.
As we have witnessed from the strategic adjustments to our commercial business development pipelines and life cycle management of our franchises, we are optimizing our capital allocation in a difficult marketplace to create an efficient organization with a critical infrastructure to succeed across all of our endeavors. With this, I look forward to seeing everyone on the next update call. Thank you. Have a great day and a great summer.